Connect with us

Biotechnology

Small Cap Biotech Stocks See Boost From Large Cap M&A

A. Lawrence

Published

on

biotech stocks to buy

Cancer has been a problem plaguing society for at least half a century. However, the fight to defeat cancer has picked up steam in the 21st century. More and more companies are making it their missions to develop treatments for many forms of cancer. From penny stocks to large-cap stocks, biotechnology companies are breaking new ground.

New Up & Comers

GT Biopharma Inc. (GTBP) is a small-cap biotech company that creates immune-oncology products. They utilize a technology platform that combines antibody-drug linkers to single-chain, bi-, tri-, and tetra-specific scFv constructs to produce treatments. One example is for carcinoma, called OXS-1615, which is a tetraspecific treatment.

Recently, GT Biopharma has been making advances for their GTB-1550 treatment. This treatment aims to treat Non-Hodgkin’s Lymphoma and Leukemia. They recently announced the results of GTB-1550’s phase I and II clinical trials. The results showed positive results including one patient becoming cancer-free post treatment.

GTBP stock

“We are pleased the patient who experienced a complete remission following treatment with GTB-1550 is doing well, and we are excited about moving forward with a GTB-1550 Phase II clinical trial for the treatment of chemotherapy-refractive B-cell malignancies,” stated Dr. Veronika Backanova, Associate Professor of Medicine, Division of Hematology, Oncology and Transplantation at the University of Minnesota.

Large Cap Influencers

Merck & Co Inc. (MRK) has been flexing its dominance as of late. The company treats hepatitis C, diabetes, HIV, and other diseases. They recently announced their plans to acquire Tilos Therapeutics. Tilos is another biopharmaceutical company that treats cancer.

Dr. Dean Li, Senior VP, Merck Research Laboratories, stated, “Tilos has developed a compelling portfolio of candidates that employ a novel approach to modulating the potent signaling molecule TGFβ by binding to latency-associated peptide, with potential applications across a range of disease indications.”

Like any type of big company, large biotech companies are setting the stage for smaller ones. One such company includes Bristol-Myers Squibb Company (BMY). Bristol-Myers is a biopharmaceutical company that creates and sells drugs for cardio and fibrotic disease, as well as cancer.

BMY stock chart

Recently, they had a 5-year follow up on their Phase 1 CA209-004 study which focused on the treatment of melanoma. The results showed long-term survival outcomes having a higher survival % with the treatment. In addition, it showed that the overall survival rate remained stable after four years or longer.

Incyte Corporation (INCY) is a healthcare company focused mainly on oncology. One of the company’s treatments includes Jakafi. This drug treats Polycythemia Vera, Myelofibrosis, and Acute Graft-Versus-Host Disease. In addition to their other treatments, Incyte announced they have treated their first patient in their FIGHT-302 Phase 3 study.

Steven Stein, M.D., Chief Medical Officer of Incyte, explained, “Most patients that present with cholangiocarcinoma, like those patients to be enrolled in the FIGHT-302 study, have an advanced form of the disease that cannot be surgically removed, and the majority do not respond to the current standard of care, demonstrating the significant need for new treatment options.”

biotech stock to buy 2019
Pursuant to an agreement between MIDAM VENTURES, LLC and GT Biopharma, Midam was hired for a period from 06/07/2019 – 7/07/2019 to publicly disseminate information about GT Biopharma including on the Website and other media including Facebook and Twitter. We were paid $100,000 (CASH) for & were paid “0” shares of restricted common shares. We may buy or sell additional shares of GT Biopharma in the open market at any time, including before, during or after the Website and Information, provide public dissemination of favorable Information. Click Here For Full Disclaimer.

Continue Reading
Click to comment

Biotechnology

Biotech Names To Know In November 2019

A. Lawrence

Published

on

best biotechnology stocks to buy sell

Biotech Stocks Have rallied since The End Of September; What’s Next?

Over the years, the biotech sector has become one of the fastest-growing sectors in the stock market and naturally, investors are keen to get hold of stocks that could follow a similar growth trajectory. However, just because a sector is growing does not mean that an investor can bet on any stock and hope to make decent returns.

In order to choose the right stock, he needs to do a lot of personal research and watch the market closely. Here is a look at three biotech stocks that investors should track closely owing to recent developments.

Sernova Corp’s (TSX:SVA) (OTC:SEOVF)

Sernova’s therapeutic approach to regenerative medicine focuses on providing direct cell therapies where the cells, transplanted within an organ-like vascularized implantable device, generates proteins, hormones or factors released into the bloodstream for treatment of diseases requiring replacement of these molecules in the body.

The company’s Cell Pouch is a novel, proprietary, scalable, implantable macro-encapsulation device designed for the long- term survival and function of therapeutic cells. At the end of October Sernova Corp. (SVA) (SEOVF) detected enduring levels of C-peptide in the bloodstream of a fasting patient in its continuing phase I/II Cell Pouch United States clinical study of type-1 diabetes. This C-peptide is a biomarker of transplanted beta-cell insulin production,

Why is this important? According to Dr. Piotr Witkowski, Director of Pancreatic, and Islet Transplant Program at the University of Chicago, “Along with the preliminary safety and early indicators of efficacy, I am excited that we are observing C-peptide levels in the patient’s bloodstream after recent transplant, not only following stimulation with a meal but also when the patient is fasting. These findings represent progress in clinical outcomes and evidence of enduring islet survival and function within Sernova’s Cell Pouch.”

Read This Full Press Release Here

Genprex (GNPX)

The first one to put in the watch list is that of Genprex Inc (NASDAQ:GNPX). On Tuesday, the company revealed preclinical data from its study of its product TUSC2 immunogene therapy. The product in question is meant for raising the effectiveness of chemotherapy and anti-PD1 in people suffering from metastatic lung cancers.

The data proved to be positive and that has naturally resulted in a rally in the stock. It is a significant development for Genprex and could potentially help the company in cornering an important portion of the gene therapy market. Hence, it is hardly a surprise that the stock has rallied by as much as 60% after hitting a session’s high of $1.09.

 Can Fite Biopharma (CANF)

The other biotech stock that has made a strong move is the Can Fite Biopharma (NYSE:CANF) stock. The biotech company announced this morning that one of its products, which is meant for the treatment of liver diseases and cancer, has been granted a patent as a sexual dysfunction medicine.

The patents have been granted by the relevant authorities in Canada, Israel, and South Korea. In addition to that, the company has also been awarded patents in Japan, China, United States, Australia, and Hong Kong. It is a highly important development for Can-Fite and it was no surprise when the stock rallied this morning. It has rallied by 3% on Tuesday on the back of the news.

top biotech stocks to watch list

Disclaimer: Pursuant to an agreement between Midam Ventures LLC and Sernova (TSX:SVA) (OTC:SEOVF), Midam has been paid $350,000 for a period from September 23, 2019 to September 22, 2020. We may buy or sell additional shares of Sernova (TSX:SVA) (OTC:SEOVF) in the open market at any time, including before, during or after the Website and Information, to provide public dissemination of favorable Information about Sernova (TSX:SVA) (OTC:SEOVF). Click Here For Full Disclaimer.

Continue Reading

Biotechnology

The Biotech Index Just Hit New Highs; Stocks To Watch

Joe Samuel

Published

on

biotechnology stocks to watch

The Biotech ETF – IBB – Just Made New November Highs, What’s Next?

Investment experts and professional money managers almost always tell people to invest across a range of experts. This is usually in order to generate bigger returns in the long term. One of the sectors that is almost always favored by professionals is the biotech sector and the simple reason behind that is the fact that the sector has managed to grow at an impressive pace.

However, in order to pick stocks, an individual would need to conduct his own research with regard to different companies. Here is a look at three biotech stocks that should be tracked closely due to recent events.

PharmaCyte Biotech (PMCB)

PharmaCyte Biotech, Inc. (PharmaCyte) is a biotechnology company developing cellular therapies for cancer and diabetes based upon a proprietary cellulose-based live cell encapsulation technology known as “Cell-in-a-Box®.” This technology will be used as a platform upon which therapies for several types of cancer and diabetes are being developed.

What Happened This Week?

top biotech stocks to buy

This week was important for the company as it hit a milestone never met. The company announced that its partner, Austrianova Singapore, has successfully completed the second and final GMP manufacturing run to produce PharmaCyte’s clinical trial product. The product is now ready for “release testing.”

The data from the “release testing” of both manufacturing runs will be included in an Investigational New Drug application (IND) and submitted to the U.S. Food and Drug Administration to support PharmaCyte’s planned clinical trial in patients with locally advanced, inoperable pancreatic cancer.

“We have cleared what was a major hurdle for us and have completed our most impactful milestone to date. Successfully completing two manufacturing runs is a milestone that has now been met as we progress toward our submission of an IND to the FDA so we can begin our clinical trial in LAPC.”

PharmaCyte’s Chief Executive Officer, Kenneth L. Waggoner

NovaBay Pharmaceuticals (NBY)

The first biotech stock to consider is that of NovaBay Pharmaceuticals, Inc. (NYSE:NBY). The NovaBay stock has been on a tear this morning owing to an important product announcement from the company. The company issued a press release this morning in which it revealed that its product NovaSight has been launched on Amazon.

The product in question is a mineral supplement and a daily vitamin that is meant for the eyes. After the announcement was made, the stock rose by as much as 26.50% in Monday’s trade and it remains one of the stocks to watch on the market today. The announcement is a significant one and could have far-reaching implications for NovaBay.

REPORT: 1 Biotech Stock is Positioning Itself for Success

BioCryst Pharmaceuticals (BCRX)

Another biotech stock that has been in the middle of a highly impressive rally in recent sessions is that of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX). The stock has gained over the course of the past three trading sessions and has generated gains of as much as 28% so far.

In a new development, the company completed a capital raise by offering its equity and managed to raise as much as $55 million. This prompted Bank of America analysts Tazeen Ahmad to upgrade the stock from neutral to buy. The capital raise and the upgrade possibly resulted in the remarkable rally in the BioCryst stock in recent days.

REPORT: 1 Biotech Stock is Positioning Itself for Success

make money with penny stocks biotech

Disclaimer: Pursuant to an agreement between MIDAM VENTURES, LLC and Complete Investment And Management LLC, a Non-affiliate Third Party, Midam was hired for a period from 07/09/2019 – 8/09/2019 to publicly disseminate information about PharmaCyte Biotech including on the Website and other media including Facebook and Twitter. We were paid $150,000 (CASH) for & were paid “0” shares of restricted common shares. We were paid an additional $150,000 (CASH) BY Complete Investment And Management LLC, a Non-affiliate Third Party, AND HAVE EXTENDED coverage for a period from 8/12/2019 – 10/15/2019. We were paid an additional $150,000 (CASH) BY Complete Investment And Management LLC, a Non-affiliate Third Party, AND HAVE EXTENDED coverage for a period from 10/16/2019 – 11/15/2019.We may buy or sell additional shares of PharmaCyte Biotech in the open market at any time, including before, during or after the Website and Information, provide public dissemination of favorable Information. Click Here For Full Disclaimer.

Continue Reading

Biotechnology

3 Biotech Stocks To Watch As Markets Gain Momentum

Joe Samuel

Published

on

biotech stocks to buy

The biotech sector has generated impressive growth over the past decade or so and consequently, many of the biotech stocks in the market have also proven to turn heads. Hence, it is not a surprise that most who look for cutting edge companies focus on the biotech sector.

In order to find the right stocks, an investor needs to do a lot of research and needs to keep a close eye on the latest developments. Here is a quick look at 3 biotech stocks that investors are watching closely this quarter.

PharmaCyte Biotech (PMCB)

PharmaCyte Biotech (PMCB) has developed a drug delivery platform that could be on the verge of a major FDA event. In fact, the news shared on November 18 by the company could be a clear indicator of such an event.

The company announced today that its partner, Austrianova Singapore (Austrianova), has successfully completed the second and final GMP manufacturing run. This was to produce PharmaCyte’s clinical trial product. The product is now ready for “release testing.”

Why Is Release Testing Important For PharmaCyte?

The data from the “release testing” of both manufacturing runs will be included in an Investigational New Drug application (IND) and submitted to the U.S. Food and Drug Administration (FDA). It essentially supports PharmaCyte’s planned clinical trial in patients with locally advanced, inoperable pancreatic cancer.

top biotech stocks to buy

PharmaCyte’s Chief Executive Officer, Kenneth L. Waggoner, commented, “Today is a great day at PharmaCyte. We have cleared what was a major hurdle for us and have completed our most impactful milestone to date. Successfully completing two manufacturing runs is a milestone that has now been met as we progress toward our submission of an IND to the FDA so we can begin our clinical trial in LAPC.

Learn more about PharmaCyte Biotech Here

Titan Medical (TMDI)

The first biotech stock that should go into the watch list is that of Titan Medical Inc. (NASDAQ: TMDI). The stock has been on an impressive over the past week or so after the company made a significant announcement.

Titan announced on November 15 that its robotic surgery system has been suspended due to the cash crunch at the company. It stated that it is now looking for options with regards to funding and until then the project will remain suspended.

[Report] 1 Biotech Stock is Positioning Itself for Success.

Investors probably believe that is a positive development since Titan would not be bleeding cash in the middle of a cash crunch and the stock has gone up by as much as 55% after the announcement was made.

Catalyst Pharmaceuticals (CPRX)

The other biotech stock that should be tracked at this point is that of Catalyst Pharmaceuticals Inc (NASDAQ: CPRX). The company announced its financial results for the third quarter on November 14 and there are two important things to keep in mind with regards to the company’s business currently.

biotech stocks to watch now Catalyst Pharmaceuticals (CPRX)

Catalyst announced that its product Firdapse is going to generate $100 million worth of sales for the full year 2019. However, that is well short of analysts’ expectations of $111 million. Additionally, the company’s upper limit for its revenues guidance for 2020 is also short of analysts’ expectations. The higher limit is projected at $155 million but that is $11 million short of analysts’ estimates.

best biotech stocks to watch this month

Disclaimer: Pursuant to an agreement between MIDAM VENTURES, LLC and Complete Investment And Management LLC, a Non-affiliate Third Party, Midam was hired for a period from 07/09/2019 – 8/09/2019 to publicly disseminate information about PharmaCyte Biotech including on the Website and other media including Facebook and Twitter. We were paid $150,000 (CASH) for & were paid “0” shares of restricted common shares. We were paid an additional $150,000 (CASH) BY Complete Investment And Management LLC, a Non-affiliate Third Party, AND HAVE EXTENDED coverage for a period from 8/12/2019 – 10/15/2019. We were paid an additional $150,000 (CASH) BY Complete Investment And Management LLC, a Non-affiliate Third Party, AND HAVE EXTENDED coverage for a period from 10/16/2019 – 11/15/2019.We may buy or sell additional shares of PharmaCyte Biotech in the open market at any time, including before, during or after the Website and Information, provide public dissemination of favorable Information. Click Here For Full Disclaimer.

Continue Reading

Join Our Newsletter

Get stock alerts, news & trending stock alerts straight to your inbox!


Privacy Policy

We keep all user information pricate & promise to never spam.*

Stock Price Free Text List

Search Stock Price (StockPrice.com)




Trending

Subscribe Now & Begin Receiving Free Stocks News, Articles, Trade Alerts & MORE, all 100% FREE!

We are your #1 source for all things Stock Market & Finance, Subscribe Below!

Privacy Policy: We will NEVER share, sell, barter, etc. any of our subscribers information for any reason ever! By subscribing you agree we can send you via email our free e-newsletter on stock market & finance related, articles, news and trade alerts. Further questions please contact privacy@stockprice.com